Roche’s VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq® (atezolizumab)

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition